Why is participation in a clinical trial advantageous?

Why is participation in a clinical trial advantageous? So there are two advantages for the patient and also for the greater good, right? Participating in the clinical trial. For the patient, when we are trying to, you know, as I said, the standard of care right Right now for MDS, newly diagnosed MDS patient is getting a hypomethylating agent and the response rate is 50%. So one in two patients still with the current standard of care don't respond. And after that we don't have many good treatment options. So the clinical trial that we have here is addition of CD47 monoclonal antibody to the hypomethylating agent. And so far in the phase one studies it is showing almost like, you know, 100% or close to 100% response by the addition of the drug. So even for a newly diagnosed MDS patient, I think participating in a trial like that, you know, not advantageous for them, but also, you know, we will know more about, you know, the disease and also the responses and to improve the care for, you know, everybody in the future.